Exscientia Past Earnings Performance
Past criteria checks 0/6
Exscientia's earnings have been declining at an average annual rate of -48.4%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 1.6% per year.
Key information
-48.4%
Earnings growth rate
-19.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 1.6% |
| Return on equity | -36.0% |
| Net Margin | -659.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Exscientia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 25 | -163 | 48 | 150 |
| 31 Dec 23 | 26 | -186 | 58 | 164 |
| 30 Sep 23 | 30 | -176 | 51 | 164 |
| 30 Jun 23 | 28 | -188 | 52 | 176 |
| 31 Mar 23 | 32 | -174 | 51 | 171 |
| 31 Dec 22 | 33 | -144 | 46 | 156 |
| 30 Sep 22 | 27 | -111 | 40 | 125 |
| 30 Jun 22 | 44 | -84 | 41 | 107 |
| 31 Mar 22 | 38 | -78 | 38 | 83 |
| 31 Dec 21 | 37 | -67 | 35 | 60 |
| 30 Sep 21 | 37 | -48 | 28 | 39 |
| 30 Jun 21 | 15 | -54 | 19 | 26 |
| 31 Mar 21 | 17 | -33 | 11 | 18 |
| 31 Dec 20 | 13 | -30 | 8 | 15 |
| 31 Dec 19 | 12 | -8 | 6 | 9 |
Quality Earnings: 0RK is currently unprofitable.
Growing Profit Margin: 0RK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RK is unprofitable, and losses have increased over the past 5 years at a rate of 48.4% per year.
Accelerating Growth: Unable to compare 0RK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 0RK has a negative Return on Equity (-36.02%), as it is currently unprofitable.